Media outlets including Newsweek reported on Monday that the Trump administration is considering removing mRNA-based COVID-19 vaccines from the U.S. market "within months." The claim stems from British cardiologist Aseem Malhotra, described as an adviser to Health and Human Services Secretary Robert F. Kennedy Jr., who told the Daily Beast that Kennedy and the president intend to withdraw the shots in one decisive move or through a phased approach. Malhotra said the prospective ban reflects growing concern inside the administration over alleged vaccine injuries and suggested the decision could be announced later in the year. Investors responded by flagging potential repercussions for Pfizer, BioNTech, Moderna and Novavax, whose shares rely heavily on COVID-19 shot sales. The White House rejected the assertions. Spokesperson Kush Desai said the administration "is relying on gold-standard science" and that any discussion of Health and Human Services policy "should be dismissed as baseless speculation" unless formally announced. Kennedy has already halted $500 million in federal grants for mRNA vaccine development and is pushing changes to the federal Vaccine Injury Compensation Program, moves that vaccine makers and public-health experts warn could undermine supply of routine immunizations. No official policy to withdraw the COVID-19 vaccines is in place, but the reports underscore industry anxiety over the administration’s evolving stance on vaccine regulation.